PDF) Statins, Fibrates and Myopathy: Pathophysiological Mechanism, Risk Factors and Laboratory Markers

Statins, Fibrates and Myopathy: Pathophysiological Mechanism, Risk Factors and Laboratory Markers

Frontiers Triglyceride and Triglyceride-Rich Lipoproteins in Atherosclerosis

Vitamins

Drug-drug-gene interactions as mediators of adverse drug reactions to diclofenac and statins: a case report and literature review

Considerations in the Approach to Appropriate Statin Selection

Myopathy with statin-fibrate combination therapy: clinical considerations - Document - Gale OneFile: Health and Medicine

Design and rationale of a randomized control trial testing the effectiveness of combined therapy with STAtin plus FENOfibrate and statin alone in non-diabetic, combined dyslipidemia patients with non-intervened intermediate coronary artery disease

Full article: Statin-induced myopathy: a review and update

Phenotype Standardization for Statin‐Induced Myotoxicity - Alfirevic - 2014 - Clinical Pharmacology & Therapeutics - Wiley Online Library

PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021

Efficacy and Safety of Pitavastatin in a Real-World Setting: Observational Study Evaluating SaFety in Patient Treated with Pitavastatin in Korea (PROOF Study)